Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales
Arcus Biosciences (RCUS) has seen a strong 200.8% return over the past year, indicating significant investor optimism, partly due to a recent partnership with Summit Therapeutics. However, the stock appears richly valued with a P/S ratio of 33.0x, significantly higher than the biotech industry average, suggesting that much of the optimism is already priced in. The company's valuation framework highlights a wide gap between its current P/S and what its risk profile would typically justify, raising questions about whether future clinical progress can support the current revenue multiple.
Investigation launched into Arcus Biosciences officers for possible self-dealing breaches
Kuehn Law, PLLC has initiated an investigation into officers and directors of Arcus Biosciences, Inc. for potential breaches of fiduciary duties through self-dealing. This investigation could result in shareholder damages and require corporate governance reforms. Long-term shareholders are advised to contact the law firm to understand their rights and potential actions.
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties due to potential self-dealing. The firm is encouraging long-term RCUS stockholders to contact them to discuss potential damages and corporate governance reforms, emphasizing that consultation and case costs are free for investors.
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS
Handelsbanken Fonder AB has acquired a new stake worth approximately $1.20 million in Arcus Biosciences, Inc. (NYSE:RCUS) during the second quarter. Institutional investors collectively own 92.89% of the company, and analysts maintain a "Moderate Buy" consensus rating with a $37.80 average price target. The company reported a quarterly loss of $0.72 per share, beating estimates, and revenues of $41 million, which exceeded expectations despite a year-over-year decrease.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant revenue drop in Q2 2026, falling to US$41 million from US$160 million a year earlier, and widened net losses. The company also cut its full-year 2026 GAAP revenue guidance to US$65 million to US$75 million. This steep decline and reduced forecast emphasize the company's reliance on its oncology pipeline, particularly casdatifan, and highlights the funding and execution risks shareholders face.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant revenue drop in Q2 2026 to US$41 million from US$160 million a year earlier, alongside a net loss of US$91 million. The company has also cut its full-year 2026 revenue guidance to US$65 million to US$75 million, which analysts believe will require a reconsideration of previous optimistic forecasts. Despite these setbacks, the company's oncology pipeline, particularly casdatifan, and a recent collaboration with Summit Therapeutics remain central to its investment narrative and future revenue potential.
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
Arcus Biosciences reported a significant drop in Q2 2026 revenue and widened net losses, leading to a lowered full-year 2026 revenue forecast of US$65 million to US$75 million. This financial update underscores the company's reliance on its oncology pipeline, particularly casdatifan, and its recent collaboration with Summit Therapeutics, which is crucial for future revenue despite ongoing execution and funding risks. Investors are advised to consider the company's ambitious revenue projections against its high cash burn and dependence on external funding, with analysts reassessing their previous optimistic forecasts.
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
Arcus Biosciences (RCUS) recently reported Q2 2026 results, with revenue of US$41 million and a net loss of US$91 million. Despite these figures, the stock has shown significant momentum, with a 16.07% 90-day return and a 24.35% year-to-date return. The company is considered 24% undervalued by many, with a fair value of $38, largely due to its promising kidney cancer pipeline, though regulatory risks and competition remain watchpoints.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside
Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. The consensus rating for RCUS remains a "Buy" from 12 covering analysts, with 9 recommending Buy and 3 recommending Hold.
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% undervalued at $38, compared to its last close of $28.96. This valuation is largely based on the potential of its kidney cancer pipeline, especially the HIF-2 alpha inhibitor, casdatifan, but faces risks from regulatory setbacks and competition.
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Arcus Biosciences and Summit Therapeutics have partnered to evaluate a combination of their investigational cancer drugs, casdatifan and ivonescimab, for clear cell renal cell carcinoma. The collaboration aims to establish a new first-line treatment and initial data is anticipated by mid-2027. Financially, Arcus appears stronger with established revenue and a longer cash runway, though both companies are pursuing significant clinical advancements.
A New Arcus Employee Receives Options With a $28.72 Exercise Price
Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share, which was the closing price on August 10, 2026. The employee also received restricted stock units for 1,450 shares. These grants were made under the Company’s 2020 Inducement Plan, consistent with the "inducement exception" under NYSE rules.
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating
Morgan Stanley has increased its price target for Arcus Biosciences (RCUS) from $22 to $23, while maintaining an Equalweight rating on the stock. Despite this adjustment, the average analyst rating for Arcus Biosciences remains a "buy" with a mean price target of $38.33. The full details of this report are available to premium subscribers.
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42
Goldman Sachs has reiterated its Buy rating on Arcus Biosciences (RCUS.US) and increased its price target to $42. This update reflects the firm's continued confidence in the company's prospects.
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead
Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration Agreement providing Gilead with exclusive licensing options on Arcus programs. While a prior option allowing Gilead to increase its stake to 35% expired in July 2025, Gilead states it currently has no specific plans for major corporate actions, but may review its investment over time.
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses
Arcus Biosciences (RCUS) reported Q2 2026 revenue of US$41m against a net loss of US$91m, indicating a substantial decline from the previous year. While the stock initially saw a pop, concerns persist regarding the company's high burn rate, reliance on partners, and concentrated pipeline focused on the casdatifan asset. The article highlights the contrasting bull and bear cases, emphasizing the potential for dilution risk despite the company's cash reserves.
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates
Arcus Biosciences (RCUS) recently reported its Q2 2026 financial results, exceeding revenue estimates despite a reported loss. The company is actively advancing its pipeline, including new clinical collaborations for casdatifan and ivonescimab in cancer treatments. An analyst from HC Wainwright also increased Arcus Biosciences' price target, while an insider sold a significant number of shares.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% Upside
Analysts have adjusted their 12-month average price target for Arcus Biosciences, Inc. (RCUS) stock down slightly from $37.91 to $37.17, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 32% from the July 31st closing price. The consensus rating from 13 covering analysts remains a "Buy," with 10 Buys and 3 Holds.
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00
Wells Fargo & Company has raised its price target for Arcus Biosciences (NYSE:RCUS) from $23.00 to $26.00, while maintaining an "equal weight" rating. This new target implies a potential downside of 5.75% from the stock's previous close. Despite this, the company has a "Moderate Buy" consensus rating from analysts with an average price target of $36.90. Arcus Biosciences recently reported better-than-expected quarterly earnings and revenue, though revenue was down year-over-year.
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M
Arcus Biosciences, Inc. (RCUS) reported Q2 revenue of $41.0 million. Wedbush adjusted its price target on Arcus Biosciences to $43 from $41, maintaining an Outperform rating. The company is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, with several investigational products in clinical development.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside
The average 12-month price target for Arcus Biosciences, Inc. stock has increased from $37.17 to $38.25, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 38% from the August 5 closing price. The consensus rating among 13 analysts remains a "Buy," with 10 Buy recommendations and 3 Holds.
Arcus Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-08-05
Arcus Biosciences, Inc. (NYSE:RCUS) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.72, which beat estimates by $0.09. The company's revenue for the quarter was $41.00M, exceeding expectations by $19.02M, despite a 74.38% year-over-year decrease. This presentation was released in conjunction with their earnings call on August 5, 2026.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) reported a Q2 loss of $0.72 per share, outperforming the Zacks Consensus Estimate of a $0.98 loss. The company also exceeded revenue expectations, posting $41 million against a consensus estimate. Despite a mixed outlook for estimate revisions, RCUS shares have increased by 20.9% year-to-date.
Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options
Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option rights over Arcus's early-stage pipeline have ended, although Gilead retains time-limited options on specific programs and a substantial equity stake. Arcus is advancing its HIF-2α inhibitor casdatifan through new collaborations while discontinuing two Phase 3 TIGIT trials, managing expenses, and expects its $775 million in cash and investments to fund operations until at least the second half of 2028.
Arcus Adds Three Kidney Cancer Trials as 2026 Data Near
Arcus Biosciences reported its second-quarter 2026 financial results, with revenues of $41 million and a net loss of $91 million. The company is strategically advancing its HIF-2α inhibitor, casdatifan, for clear cell renal cell carcinoma (ccRCC) through three new clinical trial collaborations and anticipates multiple data readouts in the second half of 2026. Arcus expects its cash reserves of $775 million to fund operations until at least the second half of 2028.
Arcus Biosciences earnings in focus as kidney cancer drug advances
Arcus Biosciences is reporting second-quarter earnings, with analysts expecting a narrower loss and increased revenue sequentially, though down year-over-year due to collaboration income. Investors are keen on updates regarding the company's lead kidney cancer candidate, casdatifan, and its clinical trials, as well as the company's cash burn. Despite past misses, Wall Street remains bullish, anticipating significant upside for the stock given the potential of its pipeline.
Arcus Biosciences Inc expected to post a loss of 90 cents a share - Earnings Preview
Arcus Biosciences Inc is projected to report a loss of 90 cents per share in its upcoming earnings. This information is provided as an earnings preview from Refinitiv. The full article can be accessed through TradingView, which offers unlimited access to news sources.
Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?
Arcus Biosciences (RCUS) recently announced a clinical collaboration with Summit Therapeutics for a kidney cancer treatment, driving significant year-to-date and annual share price returns. Despite its recent momentum and a reported undervaluation against a fair value of $35.75, the stock's high P/S ratio of 15x compared to an industry average of 10.8x suggests potential valuation risks if market sentiment shifts. Investors are encouraged to consider both the company's strong oncology pipeline, particularly its HIF-2 alpha inhibitor casdatifan, and the risks associated with trials and market competition.
BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25
BofA Securities has raised its price target for Arcus Biosciences (NYSE: RCUS) to $29 from the previous target of $25. This adjustment reflects a more optimistic outlook on the company's valuation by the financial institution.
Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?
Arcus Biosciences (RCUS) has expanded its kidney cancer collaboration with Summit Therapeutics to test a new drug combination in metastatic renal cell carcinoma. Despite a significant stock price increase of over 200% in the past year, the company is considered undervalued by some analysts, trading at a discount to fair value estimates. However, concerns remain regarding its valuation based on a high P/S ratio compared to industry averages and potential risks associated with clinical trial outcomes and regulatory hurdles.
Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in Arcus Biosciences, Inc. (NYSE:RCUS) by 1,198.8% in the first quarter, now owning 424,700 shares. Despite this institutional buying and a "Moderate Buy" consensus from analysts with an average price target of $36.40, the company reported weaker-than-expected quarterly results, and insiders have sold over $3 million worth of shares recently.
Price-Driven Insight from (RCUS) for Rule-Based Strategy
This article provides a price-driven analysis of Arcus Biosciences Inc. (RCUS) for rule-based trading strategies. It highlights weak near- and mid-term sentiment, potential resistance levels, and an exceptional short setup. The analysis offers specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo
Arcus Biosciences is expanding its ARC-20 platform with a new kidney cancer combination involving its HIF-2a inhibitor casdatifan and Summit Therapeutics' PD-1/VEGF bispecific antibody ivonescimab. This collaboration allows both companies to retain rights to their drugs while sharing costs, potentially broadening their kidney cancer pipelines. Investors are keen to see how this new combination, alongside existing alliances, will impact Arcus's investment narrative, especially concerning upcoming casdatifan data and managing ongoing financial losses.
Law firm probes Arcus Biosciences officers for possible self-dealing harming shareholders
A law firm, Kuehn Law, PLLC, is investigating officers and directors of Arcus Biosciences, Inc. for potential self-dealing and breaches of fiduciary duties. This investigation could result in shareholder damages and lead to corporate governance reforms. Long-term shareholders are advised to seek a free consultation with the law firm to enforce their rights within a limited timeframe.
RCUS|Arcus Biosciences Inc|Price:26.470|Chg%:-0.580
This article provides a comprehensive stock analysis of Arcus Biosciences Inc (RCUS) by TradingKey, highlighting its stable fundamentals, significant growth potential, and a "fairly valued" rating within the Biotechnology & Medical Research industry. The company, a clinical-stage biopharmaceutical firm focused on cancer therapies, shows high institutional ownership and a strong "Buy" rating from multiple analysts, with a target price indicating a 32% upside. The analysis also details Arcus Biosciences' strengths, such as high revenue growth and institutional buying, along with its specific pipeline of investigational products.
Arcus Biosciences Inc (RCUS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arcus Biosciences Inc (RCUS), highlighting its volatility, financial risks, and investment risks. The company's current risk assessment score is 4.64, ranking it 67 out of 385 in the Biotechnology & Medical Research industry, with a beta of 0.84 indicating it tends to underperform in up-trending markets but experience smaller declines. The analysis also details various financial metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different periods.
Arcus Biosciences Inc (RCUS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Arcus Biosciences Inc (RCUS), noting its current valuation score is 7.45, ranking 222 out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.78. Important financial data such as P/B, P/S, and P/CF ratios have not been disclosed by the company.
Three new Arcus employees receive options and 6,300 restricted stock units
Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted three new employees options to purchase a total of 12,600 shares of common stock at an exercise price of $29.73 per share, along with restricted stock units for 6,300 shares. These equity awards were issued under the Company’s 2020 Inducement Plan, leveraging the "inducement exception" of NYSE listing rules to attract new talent. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory/autoimmune diseases.
Arcus Biosciences Inc (RCUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Arcus Biosciences Inc (RCUS), focusing on its business segments. For the fiscal year 2025, the company reported $221.00 million from license and development services, accounting for 89.47% of its revenue, and $26.00 million from collaboration, making up 10.53%. Regional revenue and profit contribution data were not disclosed.
Arcus Biosciences Inc (RCUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arcus Biosciences Inc (RCUS), identifying its major shareholders and institutional holdings. It provides a breakdown of ownership by entity type and lists changes in institutional shareholding over several quarters, highlighting key investors like Gilead Sciences, Inc. and BlackRock.
Price to sales forward of Arcus Biosciences, Inc. – NYSE:RCUS
The article provides a financial metric, "Price to sales forward," for Arcus Biosciences, Inc. (NYSE:RCUS) on TradingView. It appears to be a stub or a section of a larger financial data page, as the actual value and period for the metric are not displayed but indicated as present. The content mainly consists of navigation links and disclaimers about data providers.
Does Arcus Biosciences’ (RCUS) AVEO Tie-Up Hint At A New Combo-First RCC Strategy?
Arcus Biosciences and AVEO Oncology have partnered for a clinical supply agreement to test casdatifan with tivozanib in a new ARC-20 study cohort for advanced clear cell renal cell carcinoma patients. This collaboration expands Arcus's oncology pipeline, particularly for casdatifan, but the company still faces significant challenges including high clinical spend, competition, and the need for successful regulatory outcomes. Investors need to consider the company's financial forecasts, which project revenue decline and a need for substantial earnings growth by 2029.
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41
Wedbush has reiterated its Buy rating for Arcus Biosciences (RCUS.US) and maintained its price target at $41. This indicates continued confidence from the analyst firm in the company's prospects.
Arcus Biosciences, AVEO Supply Deal for Kidney Cancer Trial
Arcus Biosciences has announced a clinical supply agreement with AVEO Oncology to evaluate their investigational small-molecule HIF-2α inhibitor, casdatifan, in combination with AVEO’s tivozanib for patients with advanced clear cell renal cell carcinoma. This collaboration aims to assess casdatifan's effectiveness in patients who have previously undergone HIF-2α-inhibitor therapy, intending to establish casdatifan as a versatile treatment option across different lines of therapy. Enrollment for this new randomized cohort within the ARC-20 study is expected to commence in the fourth quarter of 2026.
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46
LifeSci Capital has reiterated its Buy rating for Arcus Biosciences (RCUS.US) and maintained its target price at $46. This reflects a continued positive outlook from the firm regarding the company's stock performance.
Arcus Biosciences to host Q2 2026 financial results call
Arcus Biosciences will host a conference call and webcast on August 5, 2026, to discuss its financial results and pipeline updates for the second quarter ended June 30, 2026. The biopharmaceutical company focuses on developing therapies for cancer and inflammatory diseases, with key investigational medicines including casdatifan for renal cell carcinoma and quemliclustat for pancreatic cancer. Investors can access the event via dial-in or webcast.
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences (NYSE: RCUS) announced that its management will host a conference call and webcast on Wednesday, August 5th, 2026, at 1:30 PM PT / 4:30 PM ET. The call will discuss the company's financial results for the quarter ended June 30th, 2026, and provide pipeline updates regarding its cancer and autoimmune disease treatments. Arcus Biosciences is a clinical-stage biopharmaceutical company focusing on developing differentiated molecules and combination therapies.
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences will host a conference call and webcast on Wednesday, August 5th, 2026, to discuss its financial results for the second quarter of 2026 and provide pipeline updates. Investors can join the call via phone or webcast, with replay available afterward. The company focuses on developing differentiated molecules and combination therapies for cancer and inflammatory/autoimmune diseases.
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
HC Wainwright has increased its price target for Arcus Biosciences (NASDAQ: RCUS) from $32 to $45, while maintaining a Buy rating. This adjustment reflects the company's aggressive expansion into first-line clear cell renal cell carcinoma (ccRCC) development with its drug casdatifan. The analyst's updated forecast incorporates potential peak global revenues of $2.2 billion for 1L ccRCC, in addition to previously modeled revenues for other patient groups.
Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy
Arcus Biosciences (RCUS) saw its stock jump 5.5% to $28.88 on Monday after HC Wainwright & Co. raised its price target from $32 to $45 while maintaining a Buy rating. This bullish analyst action, coupled with increased trading volume, signifies renewed investor confidence in the biotechnology company's oncology and immunotherapy pipeline. Investors are now watching for upcoming clinical data and partnership announcements to validate the firm's optimistic outlook.
